| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | Synshandicap
> Synshandicap | Regulatorisk partnerskab
> Arbejde med regulerende myndigheder | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | Synshandicap
> Makuladegeneration | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Neurologisk
> Multipel sklerose | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | Respiratorisk
> KOL | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | Respiratorisk
> Astma og allergi | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | Respiratorisk
> Astma og allergi | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | Hud
> Hudtilstande: de fleste typer | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | Kræft
> Kræft: blod | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: de fleste typer | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | Gastrointestinal
> Gastrointestinal: de fleste typer | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | Kardiovaskulær
> Hjerte-kar-sygdomme & hjertetilstande | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Generelt helbred
> Generelt helbred | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | Kræft
> Kræft: hud | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 5.000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Patientadvokatur
> Sundhedsaktivist | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Patientadvokatur
> Sundhedsaktivist | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | Respiratorisk
> Lungesygdomme | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | Sjælden
> Sjældne sygdomme: andre | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 1.000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Kræft
> Kræft: bryst | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Kræft
> Kræft: de fleste typer | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 1.000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Hud
> Alopeci | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 5.000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Kræft
> Kræft: blod | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 5.000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | Kræft
> Kræft: blære | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | Synshandicap
> Synshandicap | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Kræft
> Kræft: de fleste typer | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 1.000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Sjælden
> Pompes sygdom | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Kræft
> Kræft: kolorektal | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Generelt helbred
> Fedme | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | Generelt helbred
> Fedme | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | Patientuddannelse
> Patientuddannelse | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | Respiratorisk
> Lungesygdomme | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | Reumatisk
> Lupus | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Synshandicap
> Synshandicap | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | Handicap
> Handicap: andet | Regulatorisk partnerskab
> Bidrag til ansøgninger om markedsføringstilladelse | 5.000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Ældre mennesker
> Ældre mennesker | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 100.000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Kræft
> Kræft: bryst | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 100.000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | Sjælden
> Sjældne sygdomme: blod | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | Blod
> Seglcelleanæmi | Regulatorisk partnerskab
> Med andre sundhedsforkæmpere | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Synshandicap
> Makuladegeneration | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 100.000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Ældre mennesker
> Ældre mennesker | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 10.000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | Hud
> Hudtilstande: de fleste typer | Indflydelse på politik og lovgivning
> Deltag i offentlige høringer og konsultationer | 100.000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | Reumatisk
> Sklerodermi | Indflydelse på politik og lovgivning
> Deltag i offentlige høringer og konsultationer | 5.000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | Sjælden
> Sjældne sygdomme: genetisk | Indflydelse på politik og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 1.000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Ældre mennesker
> Ældre mennesker | Indflydelse på politik og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 100.000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Ældre mennesker
> Ældre mennesker | Indflydelse på politik og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 10.000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Kræft
> Kræft: blod | Indflydelse på politik og lovgivning
> Håndtering af barrierer/anomalier i medicinsk behandling | 1.000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Synshandicap
> Synshandicap | Indflydelse på politik og lovgivning
> Håndtering af barrierer/anomalier i medicinsk behandling | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Kræft
> Kræft: blod | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 5.000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Patientadvokatur
> Sundhedsaktivist | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurologisk
> Epilepsi | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 5.000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Kræft
> Kræft: de fleste typer | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 1.000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | Kræft
> Kræft: blod | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 5.000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Sjælden
> Pompes sygdom | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Kræft
> Kræft: blod | Prisfastsættelse og overkommelighed
> Deltag i forhandlinger med prisrevisionsnævnet | 5.000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | Immun
> Primære immundefekter | Prisfastsættelse og overkommelighed
> Deltag i forhandlinger med prisrevisionsnævnet | 5.000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Ældre mennesker
> Ældre mennesker | Prisfastsættelse og overkommelighed
> Deltag i forhandlinger med prisrevisionsnævnet | 10.000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | Synshandicap
> Synshandicap | Prisfastsættelse og overkommelighed
> Deltag i forhandlinger med prisrevisionsnævnet | 100.000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | Kræft
> Kræft: blod | Prisfastsættelse og overkommelighed
> Opfordring til reducerede salgspriser fra producenter | 10.000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Immun
> Primære immundefekter | Prisfastsættelse og overkommelighed
> Sporing og overvågning af lægemiddelpriser/lægemiddelmangler | 5.000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurologisk
> Epilepsi | Prisfastsættelse og overkommelighed
> Sporing og overvågning af lægemiddelpriser/lægemiddelmangler | 5.000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Kræft
> Kræft: de fleste typer | Prisfastsættelse og overkommelighed
> Sporing og overvågning af lægemiddelpriser/lægemiddelmangler | 1.000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | Mental sundhed
> Mental helbred: stemningsforstyrrelser | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 10.000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Immun
> Primære immundefekter | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 5.000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | Neurologisk
> Epilepsi | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorisk
> Lungefibrose | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 100.000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | Synshandicap
> Synshandicap | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Sjælden
> Pompes sygdom | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | Hud
> Hudtilstande: de fleste typer | Prisfastsættelse og overkommelighed
> Deltage i oplysningskampagner | 100.000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Kræft
> Kræft: blod | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 1.000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | Reumatisk
> Lupus | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 5.000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Patientadvokatur
> Sundhedsaktivist | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | Sjælden
> Sjældne sygdomme: andre | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 1.000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurologisk
> Epilepsi | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Kræft
> Kræft: de fleste typer | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 1.000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Kræft
> Kræft: blod | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 5.000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | Synshandicap
> Synshandicap | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | Kræft
> Kræft: blod | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 5.000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Generelt helbred
> Fedme | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 100.000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | Reumatisk
> Lupus | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Ældre mennesker
> Ældre mennesker | Forbedring af adgangsveje
> Fortaler for bredere vaccinationsadgang | 10.000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | Synshandicap
> Synshandicap | Forbedring af adgangsveje
> Håndter uligheder i adgang og administration | 100.000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | Kræft
> Kræft: sarkom | Forbedring af adgangsveje
> Forbedring af adgangen til sjældne/ultrasjældne behandlinger | 5.000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Patientadvokatur
> Sundhedsaktivist | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Hud
> Alopeci | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | 5.000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Sjælden
> Pompes sygdom | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Generelt helbred
> Fedme | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | 100.000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Patientadvokatur
> Sundhedsaktivist | Evidensbaseret patientinput
> Lever Real-World Evidence (RWE) til regulatoriske myndigheder | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | Reumatisk
> Lupus | Evidensbaseret patientinput
> Udnyt patienthistorier og fortællinger om levede erfaringer | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Generelt helbred
> Generelt helbred | Evidensbaseret patientinput
> Udnyt patienthistorier og fortællinger om levede erfaringer | 10.000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Patientadvokatur
> Sundhedsaktivist | Evidensbaseret patientinput
> Udnyt patienthistorier og fortællinger om levede erfaringer | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | Kræft
> Kræft: de fleste typer | Evidensbaseret patientinput
> Udnyt patienthistorier og fortællinger om levede erfaringer | 1.000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Kræft
> Kræft: de fleste typer | Evidensbaseret patientinput
> Udnyt patienthistorier og fortællinger om levede erfaringer | 1.000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Patientadvokatur
> Sundhedsaktivist | Evidensbaseret patientinput
> Gennemfør undersøgelser/forskning for at generere data | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | Synshandicap
> Synshandicap | Evidensbaseret patientinput
> Gennemfør undersøgelser/forskning for at generere data | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV og seksuel sundhed | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: de fleste typer | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 100.000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | Ældre mennesker
> Ældre mennesker | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 10.000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | Kræft
> Kræft: blod | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 5.000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | Kræft
> Kræft: sarkom | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 5.000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurologisk
> Epilepsi | Institutionel styring
> Effektivt arbejde i netværk med flere interessenter | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV og seksuel sundhed | Opretholdelse af patientrettigheder/forbedring af livskvalitet
> Beskyttelse/forbedring af patientoplevelsen | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | HIV
> HIV | Opretholdelse af patientrettigheder/forbedring af livskvalitet
> Beskyttelse/forbedring af patientoplevelsen | 1.000 | Local | Regularly | 119045557717 |
interaktioner
handlinger & fortalervirksomhed
36 omtaler
